Compare LAMR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAMR | ARWR |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 12.4B |
| IPO Year | 1999 | 2009 |
| Metric | LAMR | ARWR |
|---|---|---|
| Price | $147.82 | $70.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $136.00 | $83.40 |
| AVG Volume (30 Days) | 417.5K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | 63.92 | ★ 99.80 |
| EPS | ★ 2.58 | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $57.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $114.45 | $28.48 |
| 52 Week High | $166.33 | $95.49 |
| Indicator | LAMR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 38.76 |
| Support Level | $148.48 | $70.03 |
| Resistance Level | $155.11 | $81.23 |
| Average True Range (ATR) | 2.10 | 3.16 |
| MACD | -0.01 | -0.72 |
| Stochastic Oscillator | 31.09 | 7.20 |
Lamar Advertising Co is an outdoor advertising company that operates as a real estate investment trust. It is engaged in the outdoor advertising business, operating outdoor advertising displays and logo signs mainly near highway exits, delivering brand-name information on available gas, food, lodging, and camping services. Included in the company's logo sign business are tourism signing contracts. It also provides transit advertising services in airport terminals, on bus shelters, benches, and buses. The company manages its operations through three operating segments: Billboard, which generates maximum revenue, Logo, and Transit Advertising. Geographically, it operates in the United States and Canada.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.